Neuralstem President and CEO to Present 2013 Trials Overview at 2013 Biotech Showcase

 Neuralstem President and CEO to Present 2013 Trials Overview at 2013 Biotech

Updates on Upcoming ALS Phase II - NSI-189 Phase Ib - Stroke Phase I/II in

Live Audio Webcast to Air on Tuesday, January 8, at 3:45 p.m. PT

PR Newswire

ROCKVILLE, Md., Jan. 4, 2013

ROCKVILLE, Md., Jan. 4, 2013 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR)
announced that President and CEO Richard Garr will present at the fifth annual
Biotech Showcase in San Francisco on Tuesday, January 8, 3:45 p.m. PT, in Room
Powell. Garr will present a business overview, including a first look at the
Phase I/II Stroke/NSI-566 cell therapy trial expected to commence in Beijing
within several weeks. Garr will also provide an update on the company's ALS
cell therapy trial and plans for the Phase II. The trial's investigators
recently announced a substantial grant for the Neuralstem ALS Phase II trial
from the National Institutes of Health (NIH). Garr will also update the trial
progress of its first-in-class neurogenic NSI-189 small molecule drug which
stimulates new neuron growth in the hippocampus, currently in a Phase Ib major
depressive disorder (MDD) trial.


The audio webcast will be available in real-time at archived for one year. The
webcast link will also be posted on the Investor Center home page on
Neuralstem's website:

The 2013 Biotech Showcase will be held at the Parc 55 Wyndham Hotel in San
Francisco, January 7-9. For more information, see:

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem
cells of the human brain and spinal cord in commercial quantities, and the
ability to control the differentiation of these cells constitutively into
mature, physiologically relevant human neurons and glia. Neuralstem completed
dosing of the last patient in an FDA-approved Phase I safety clinical trial
for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's
disease, in August 2012; the trial ends six months after that last surgery.
Neuralstem has been awarded orphan status designation by the FDA for its ALS
cell therapy.

In addition to ALS, the company is also targeting major central nervous system
conditions with its NSI-566 cell therapy platform, including spinal cord
injury, ischemic stroke and glioblastoma (brain cancer). The company has
submitted an IND (Investigational New Drug) application to the FDA for a Phase
I safety trial in spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell
lines suitable for the systematic screening of large chemical libraries.
Through this proprietary screening technology, Neuralstem has discovered and
patented compounds that may stimulate the brain's capacity to generate new
neurons, possibly reversing the pathologies of some central nervous system
conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its
first neurogenic small molecule compound, for the treatment of major
depressive disorder (MDD).Additional indications could include chronic
traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress
disorder (PTSD).

For more information, please visit or connect with us on
Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. Investors are cautioned that such forward-looking statements in this
press release regarding potential applications of Neuralstem's technologies
constitute forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development and
commercialization of potential products, uncertainty of clinical trial results
or regulatory approvals or clearances, need for future capital, dependence
upon collaborators and maintenance of our intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential factors that
could affect our results and other risks and uncertainties are detailed from
time to time in Neuralstem's periodic reports, including the annual report on
Form 10-K for the year ended December 31, 2011 and the quarterly report on
Form 10-Q for the period ended September 30, 2012.

SOURCE Neuralstem, Inc.

Contact: Deanne Eagle - Media Relations, +1-917-837-5866; Susan Roush -
Investor Relations, +1-818-222-8330
Press spacebar to pause and continue. Press esc to stop.